Literature DB >> 27895810

Chemotherapy research for metastatic prostate cancer.

Anil Kapoor1, Sebastien J Hotte2.   

Abstract

Entities:  

Year:  2016        PMID: 27895810      PMCID: PMC5120982          DOI: 10.5489/cuaj.4055

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  12 in total

1.  Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.

Authors:  Daniel P Petrylak; Donna Pauler Ankerst; Caroline S Jiang; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford
Journal:  J Natl Cancer Inst       Date:  2006-04-19       Impact factor: 13.506

2.  Overcoming chemotherapy resistance in prostate cancer.

Authors:  Ravi A Madan; Sumanta Kumar Pal; Oliver Sartor; William L Dahut
Journal:  Clin Cancer Res       Date:  2011-06-15       Impact factor: 12.531

3.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

Authors:  Johann Sebastian de Bono; Stephane Oudard; Mustafa Ozguroglu; Steinbjørn Hansen; Jean-Pascal Machiels; Ivo Kocak; Gwenaëlle Gravis; Istvan Bodrogi; Mary J Mackenzie; Liji Shen; Martin Roessner; Sunil Gupta; A Oliver Sartor
Journal:  Lancet       Date:  2010-10-02       Impact factor: 79.321

4.  Is there a role for the assessment of health-related quality of life in the clinical evaluation of novel cytostatic agents?: Commentary re: P. M. LoRusso, Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin. Cancer Res., 9: 2040-2048, 2003.

Authors:  Linda J Patrick-Miller
Journal:  Clin Cancer Res       Date:  2003-06       Impact factor: 12.531

5.  Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.

Authors:  Robert J van Soest; Ellen S de Morrée; Charlotte F Kweldam; Corrina M A de Ridder; Erik A C Wiemer; Ron H J Mathijssen; Ronald de Wit; Wytske M van Weerden
Journal:  Eur Urol       Date:  2014-12-04       Impact factor: 20.096

6.  Measuring the side effects of taxane therapy in oncology: the functional assesment of cancer therapy-taxane (FACT-taxane).

Authors:  David Cella; Amy Peterman; Stacie Hudgens; Kimberly Webster; Mark A Socinski
Journal:  Cancer       Date:  2003-08-15       Impact factor: 6.860

7.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

Authors:  Daniel P Petrylak; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Donna Berry; Carol Moinpour; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

8.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

9.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.

Authors:  Christopher J Sweeney; Yu-Hui Chen; Michael Carducci; Glenn Liu; David F Jarrard; Mario Eisenberger; Yu-Ning Wong; Noah Hahn; Manish Kohli; Matthew M Cooney; Robert Dreicer; Nicholas J Vogelzang; Joel Picus; Daniel Shevrin; Maha Hussain; Jorge A Garcia; Robert S DiPaola
Journal:  N Engl J Med       Date:  2015-08-05       Impact factor: 91.245

10.  Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.

Authors:  Nicholas D James; Matthew R Sydes; Noel W Clarke; Malcolm D Mason; David P Dearnaley; Melissa R Spears; Alastair W S Ritchie; Christopher C Parker; J Martin Russell; Gerhardt Attard; Johann de Bono; William Cross; Rob J Jones; George Thalmann; Claire Amos; David Matheson; Robin Millman; Mymoona Alzouebi; Sharon Beesley; Alison J Birtle; Susannah Brock; Richard Cathomas; Prabir Chakraborti; Simon Chowdhury; Audrey Cook; Tony Elliott; Joanna Gale; Stephanie Gibbs; John D Graham; John Hetherington; Robert Hughes; Robert Laing; Fiona McKinna; Duncan B McLaren; Joe M O'Sullivan; Omi Parikh; Clive Peedell; Andrew Protheroe; Angus J Robinson; Narayanan Srihari; Rajaguru Srinivasan; John Staffurth; Santhanam Sundar; Shaun Tolan; David Tsang; John Wagstaff; Mahesh K B Parmar
Journal:  Lancet       Date:  2015-12-21       Impact factor: 79.321

View more
  1 in total

Review 1.  Safety and Efficacy of First-Line Treatments for Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Indirect Comparison.

Authors:  Haofeng Zheng; Jialiang Chen; Wenhan Qiu; Sijie Lin; Yanxiong Chen; Guancan Liang; Youqiang Fang
Journal:  Biomed Res Int       Date:  2017-12-07       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.